PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer-A GERCOR Study.

Affiliation auteurs!!!! Error affiliation !!!!
TitrePEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer-A GERCOR Study.
Type de publicationJournal Article
Year of Publication2015
AuteursChibaudel B, Maindrault-Goebel F, Andre T, Bachet JBaptiste, Louvet C, Khalil A, Dupuis OJean Marie, Hammel P, Garcia MLine, Bennamoun M, Brusquant D, Arbaud C, Wang Y-W, Yeh G, Bonnetain F, de Gramont A, GERCOR
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume33
Date PublishedJAN 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2015.33.3_suppl.751